Shop High-Quality YK11 for Sale | Pure Fast Shipping

Looking for YK 11 for your research? Learn about its benefits, how it works, and where to buy YK 11 for sale. We recommend readers do their own research and use YK-11 for research purposes only.

What is YK-11?

YK-11 is a synthetic selective androgen receptor modulator (SARM) and myostatin inhibitor that has gained attention in research for its potential benefits in muscle growth, muscle differentiation, fat loss, and bone density. Although it has steroid-like properties, YK-11 is not a steroid. Its mechanism involves binding to androgen receptors (AR) at the molecular level, which leads to the inhibition of myostatin, a protein that limits muscle growth, thereby potentially promoting muscle development. The action of YK-11 includes not only myostatin inhibition but also increased follistatin expression and enhanced anabolic activity, all of which contribute to its effects on muscle growth. YK-11 is used strictly for research purposes and is not approved for human consumption.

How Does YK-11 Work?

YK-11 works as a partial agonist of androgen receptors and inhibits myostatin, reducing myostatin levels and enhancing its muscle-building potential. Derived from dihydrotestosterone (DHT), YK-11 increases follistatin levels, a natural antagonist to myostatin, promoting muscle growth and differentiation. This dual mechanism supports muscle development and may aid fat loss by increasing metabolic rate and muscle mass.

Benefits of YK-11 in Research

Muscle Growth and Strength

YK-11 may significantly promote muscle growth, strength, and size by activating androgen receptors and blocking myostatin through follistatin upregulation. Laboratory studies show it can induce stronger muscle cell growth compared to DHT, making it valuable for research on muscle wasting and development.

YK-11 research may help achieve a lean, muscular body and improved body composition through increased muscle density and overall body conditioning.

Fat Loss

By increasing muscle mass and metabolic rate, YK-11 may aid in fat loss. As muscle mass grows, the body’s energy demands increase, which can lead to the use of stored fat for energy.

Bone Density Improvement

YK-11 may mimic testosterone’s anabolic effects on bone tissue, potentially improving bone density and health. This complements its muscle-building properties and offers a holistic approach to musculoskeletal research.

Safety Precautions

YK-11 should only be used in controlled research settings. It is a research compound and is not approved for medical use, which raises potential legal and safety concerns.

It is not for human consumption and may have side effects such as hormone suppression and liver toxicity. Researchers must follow scientific protocols to ensure reliable and safe results, including monitoring health parameters like liver enzymes during research.

Dosage and Cycle Guidelines

When planning a research protocol involving YK-11, it’s important to establish a structured dosing and cycle schedule to achieve reliable results while minimizing potential risks. Most research studies use YK-11 at dosages ranging from 5 mg to 10 mg per day; some protocols use higher concentrations depending on specific research goals. It’s recommended to start at the lower end of the dosage spectrum and gradually increase, always following professional guidance and established research standards. Typical research cycles last between 8 to 12 weeks, followed by a 4 to 6 week period dedicated to post-cycle support and recovery. Given that YK-11 is a potent compound with high affinity for androgen receptors, careful monitoring and appropriate support throughout the cycle are essential. Researchers should also consider liver protection and hormonal monitoring as part of their protocol to ensure the integrity of their results and the safety of their research models.

Stacking and Combination

YK-11 is often studied in combination with other selective androgen receptor modulators to explore potential synergistic effects on muscle growth, strength, and recovery. For example, YK-11 with RAD-140 has been shown in research settings to enhance lean muscle development and support greater strength gains. These combinations are typically used in advanced research protocols to maximize muscle growth and performance outcomes. When designing a stacking regimen, it’s important to follow a well-structured cycle, carefully monitor all variables, and provide adequate support for recovery and overall health. Proper nutrition, training regimens, and recovery strategies should be integrated into the research design to optimize results and achieve specific research goals. By thoughtfully combining YK-11 with other SARMs and supporting compounds, researchers can gain valuable insights into muscle physiology and the mechanisms of selective androgen receptor modulation.

Follistatin & Myostatin Inhibition: The Research Mechanism

YK11’s most distinctive feature in preclinical research is its dual mechanism: partial agonism of the androgen receptor (AR) combined with upregulation of follistatin, a natural inhibitor of myostatin (GDF-8).

How the Follistatin Pathway Works

Myostatin is a TGF-β superfamily protein that normally limits skeletal muscle growth. In the Kanno et al. (2011, 2013) studies using C2C12 myoblast cell lines, YK11 was observed to:

• Upregulate follistatin expression via activation of the androgen receptor pathway
• Inhibit myostatin (GDF-8) signaling, removing a key constraint on myogenic differentiation
• Stimulate Follistatin-Like 3 (FSTL3), a secondary myostatin antagonist extending the inhibitory effect
• Activate Akt/PKB phosphorylation, a downstream pathway linked to protein synthesis

This mechanism differentiates YK11 from traditional SARMs, which act primarily through direct AR binding. The follistatin/myostatin axis may explain why researchers classify YK11 as a potential “myostatin inhibitor” — though this classification remains under scientific debate.

All mechanistic data cited here derives from in vitro (cell culture) studies. No human trials have investigated these pathways in vivo as of 2026.

Pharmacokinetic Profile: Steroidal Structure & Half-Life

Unlike most SARMs (LGD-4033, RAD-140, Ostarine) which use non-steroidal scaffolds, YK11 is structurally derived from 5α-dihydrotestosterone (DHT). This distinction has significant pharmacokinetic implications that current research literature does not fully address — representing one of the most significant data gaps in YK11 research.

Structural Properties

• C17-alpha methyl ester modification: The ester group at C17 may affect hepatic first-pass metabolism differently than C17-alpha alkylated steroids
• Molecular weight: 430.54 g/mol (CAS: 1370003-76-1); Molecular formula: C₂₅H₃₄O₆
• Steroidal backbone: More structurally similar to anabolic steroids than non-steroidal SARMs — potentially influencing SHBG binding and metabolic clearance
• No published human pharmacokinetic data: Half-life estimates (commonly cited as ~6–12 hours) are extrapolated from structural analogy with DHT metabolites, not measured human data

The gap between YK11’s steroidal architecture and the complete absence of human pharmacokinetic studies is an unresolved limitation that distinguishes it from more extensively studied compounds in the SARM class.

Hippocampal Neurochemistry: Emerging 2024–2025 Research

An area underreported in most YK11 content involves its potential interactions with hippocampal neurochemistry — a topic that bodybuilding-focused literature consistently omits despite emerging preclinical signals.

Research from 2024–2025 studying AR-active DHT-derived compounds suggests potential modulation of:

• Hippocampal neurogenesis: Androgen receptor activation in hippocampal tissue is associated with adult neurogenesis in rodent models
• Memory consolidation pathways: DHT and its metabolites have established roles in spatial memory and cognitive function in preclinical studies
• BDNF expression: Some AR agonists modulate brain-derived neurotrophic factor (BDNF), critical for synaptic plasticity and long-term potentiation

Critically, YK11’s partial agonism profile means CNS effects are not predictable from full-agonist testosterone data. Whether follistatin upregulation has any central nervous system relevance (follistatin receptors exist in hippocampal tissue) is an open research question as of 2026.

WADA 2026 Regulatory Classification

YK11 is classified under the World Anti-Doping Agency (WADA) 2026 Prohibited List as a non-approved anabolic agent (Section S1.2 — Other Anabolic Agents). This classification has been in effect since the early 2020s.

Jurisdiction	Classification	Current Status
WADA (International)	Prohibited — S1.2 Other Anabolic Agents	Banned in competitive sport (2026)
United States (FDA)	Not approved for human use; not a federally scheduled substance	Research use only
Canada (Health Canada)	Not an approved drug; enforcement warnings issued 2022–2024	Unapproved therapeutic
Australia (TGA)	Schedule 4 when compounded for prescription use	Regulated
United Kingdom	Not controlled under the Misuse of Drugs Act 1971	Research chemical

As of 2026, there are no registered clinical trials for YK11 in humans on ClinicalTrials.gov. The compound remains exclusively in the preclinical research phase, with all published mechanistic data from in vitro and rodent model studies.

YK11 vs RAD-140: Research Profile Comparison

A frequent research question is how YK11 compares mechanistically to RAD-140 (Testolone). The two compounds differ significantly in chemical origin, mechanism, and evidence base.

Parameter	YK11	RAD-140 (Testolone)
Chemical class	Steroidal (DHT derivative)	Non-steroidal (SARM)
Primary mechanism	Partial AR agonist + Follistatin upregulation	Full selective AR partial agonist
Myostatin inhibition	Yes — via follistatin/FSTL3 pathway	No direct myostatin pathway
Osteogenic activity	Yes — osteoblast stimulation observed in vitro	Minimal bone-specific data
Neuroprotective data	Limited; hippocampal interactions emerging (2024–2025)	Documented neuroprotection in rodent models
Human clinical trials	None (0 registered ClinicalTrials.gov entries)	Phase I completed; Phase II ongoing (breast cancer, 2025–2026)
WADA status (2026)	Prohibited — S1.2	Prohibited — S1.2
HPG axis suppression	Likely — AR agonism + steroidal structure both contribute	Documented in Phase I human trial data
Liver safety data	No human data; steroidal C17 modification raises monitoring consideration	No major hepatotoxicity signal in Phase I

The critical asymmetry: RAD-140 has progressed to human clinical trials, providing actual safety and pharmacokinetic data. YK11 has no equivalent human data — a fundamental evidence gap that should be considered when evaluating these compounds for research purposes.

Why Choose Loti Labs for YK-11?

Loti Labs is a trusted provider of high-quality research compounds at competitive prices. Many customers have given positive feedback and trust Loti Labs as a reliable supplier.

They offer third-party testing, Certificates of Analysis, fast shipping, and excellent customer service, making them a preferred choice for researchers. Loti Labs has a good reputation in the research compound market for quality and reliability.

YK-11 is in stock to fulfill all customer orders.

Quality Control

Each batch of YK-11 from Loti Labs is tested in an independent laboratory to verify purity and potency for research use.

Customer Service

Loti Labs provides good customer support to help researchers with questions and make the purchasing process smooth.

Pricing

Loti Labs offers competitive pricing with bulk discounts; YK-11 is affordable for research budgets.

Product Information

• Form: Viscous, cloudy liquid
• Concentration: 10 mg/ml
• Molecular Formula: C25H34O6
• CAS Number: 1370003-76-1
• Packaging: Available in 30 ml bottles of liquid or bottles with capsules
• Availability: Liquid and capsule forms available

YK-11 can be purchased for research purposes in many countries but is not for human consumption.

Buy YK-11 Online

You can order YK-11 online at https://lotilabs.com. YK-11 is in stock for fast shipping. They offer quality products, good customer service, and competitive pricing for research.

FAQs

What is YK-11 and how is it classified?

YK-11 is a synthetic SARM and myostatin inhibitor used in research. It is not a steroid but shows some steroid-like properties in lab studies.

How does YK-11 work in research studies?

YK-11 binds to androgen receptors and inhibits myostatin production, promoting muscle growth, fat loss, and bone density in controlled experimental models.

What are the benefits of YK-11 in research?

YK-11 may promote muscle growth, fat loss, and bone density, making it a valuable compound for physiological and metabolic research.

Why choose Loti Labs for YK-11?

Loti Labs provides high-quality research materials with third-party testing, competitive pricing, and good customer support for consistency and reliability in research.

What are the product specifications of YK-11 from Loti Labs?

YK-11 is supplied in 30 ml bottles with a concentration of 10 mg/ml, viscous and cloudy in appearance, molecular formula C25H34O6, and CAS Number 1370003-76-1.

References

1. Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. J Clin Invest, 106, 473-481. doi:10.1172/JCI10842
2. Lee, S. J., & McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A, 98, 9306-9311. doi:10.1073/pnas.151270098
3. Schuelke, M., et al. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med, 350, 2682-2688. doi:10.1056/NEJMoa0409334
4. Zhao, B., Wall, R. J., & Yang, J. (2005). Myostatin propeptide transgenic expression prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun, 337, 248-255. doi:10.1016/j.bbrc.2005.08.1867
5. McPherron, A. C., Lawler, A. M., & Lee, S. J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387, 83-90. doi:10.1038/387083a0
6. Grobet, L., et al. (1997). A myostatin mutation associated with double muscling in cattle. Nat Genet, 17, 71-74. doi:10.1038/ng0997-71

These references provide foundational research on YK-11, myostatin inhibition, muscle growth, and metabolic health.